New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:18 EDTNBIXNeurocrine initiated with a Buy at Nomura
Target $23.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
11:38 EDTNBIXOptions with increasing implied volatility
Subscribe for More Information
December 16, 2014
07:17 EDTNBIXNeurocrine named a top pick for 2015 at Piper Jaffray
Piper Jaffray named Neurocrine a top pick for 2015 and raised its price target for shares to $29 from $26. Piper expects the company's clinical data catalysts between now and the end of 2015 to be mostly or all positive. It reiterates an Overweight rating on the name.
December 15, 2014
10:36 EDTNBIXOptions with increasing implied volatility
Subscribe for More Information
December 12, 2014
12:05 EDTNBIXOptions with increasing implied volatility
Subscribe for More Information
December 11, 2014
12:24 EDTNBIXNeurocrine volatility elevated on sharp rally
Neurocrine overall option implied volatility of 109 compares to its 26-week average of 82 according toTrack Data, suggesting large price movement.
10:21 EDTNBIXHigh option volume stocks
Subscribe for More Information
December 10, 2014
08:04 EDTNBIXNeurocrine completes pilot clinical trial of hyperplasia candidate
Neurocrine Biosciences' NBI-77860, a proprietary corticotropin releasing factor 1 receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia, a disease that affects approximately 20,000-30,000 people in the U.S. The company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH, the 1401 Study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use